Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

CDK Global Inc (CDK): Former Pershing Square Employee Targets Post-Spinoff Company

Scott Ferguson‘s Sachem Head Capital has disclosed a new position in CDK Global Inc (NASDAQ:CDK), a company that was recently spun-off from Automatic Data Processing (NASDAQ:ADP). The hedge fund disclosed an activist stake that amasses around 12.65 million shares of the company, which represent 7.88% of the company. Moreover, the fund revealed holding some 3.15 million shares of common stock held under cash-settled total return swaps. In this way, the total stake contains 15.80 million shares, which represent around 9.84% of the common stock.

CDK Global

Sachem Head Capital is a relatively small hedge fund with a concentrated equity portfolio worth over $979.4 million. Mr. Ferguson, prior to founding Sachem, was employed at Bill Ackman‘s Pershing Square and many of Sachem’s positions are represented by companies that have Pershing Square among their largest shareholders. For example, during the second quarter, the fund initiated a stake in Allergan, Inc. (NYSE:AGN), a company that Mr. Ackman currently has an aggresive proxy fight with and tries to acquire.  Moreover, Sachem also owns 811,500 shares of Air Products & Chemicals, Inc. (NYSE:APD) (it is the second-largest stake in terms of value), which is also one of the largest positions in Pershing Square’s equity portfolio.

Since Sachem’s stake in CDK Global Inc (NASDAQ:CDK) is activist by nature, the investor said that it plans to discuss with the management, board of directors and other shareholders regarding the company’s governance, management, operations, and the future of the company. However, it is still not very clear what the investor’s plans regarding the company are and it is even possible that the stake is filed as activist due to the large size of the position.

CDK Global Inc (NASDAQ:CDK) went public at the end of last month and since then the stock picked up around 4.9%. The company is engaged in technology and digital marketing and advertising solutions to the automotive retail industry. A couple of days after Sachem initiated a stake, CDK Global Inc (NASDAQ:CDK) anounced its expectations for the fiscal 2015, saying that it expects its revenue to growth by around 7%-8% on the year, from some $1.97 billion for the fiscal 2014. Moreover, the net earnings are expected to grow between 6% and 8% on the year, versus $1.29 for the previous fiscal year.

With this in mind, CDK Global Inc (NASDAQ:CDK) represents an attractive investment for Sachem Head Capital, even if the investor will not attempt any steps regarding the company’s shareholder value. Nevertheless, being targeted by activist investors is always a good sign that can bring more value to the stock, which is why it is important to monitor this story closer as it develops.

Disclosure: none

Warren Buffett and BillionairesFree Report: Warren Buffett and 12 Billionaires Are Crazy About These 7 Stocks

Let Warren Buffett, David Einhorn, George Soros, and David Tepper WORK FOR YOU. If you want to beat the low cost index funds by an average of 6 percentage points per year look no further than Warren Buffett’s stock picks. That’s the margin Buffett’s stock picks outperformed the market since 2008. In this free report, Insider Monkey’s market beating research team identified 7 stocks Warren Buffett and 12 other billionaires are crazy about. CLICK HERE NOW for all the details.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!